BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miller S, Kulkarni S, Ciesielski A, Nikas SP, Mackie K, Makriyannis A, Straiker A. Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure. Pharmaceuticals (Basel) 2018;11:E50. [PMID: 29786643 DOI: 10.3390/ph11020050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Mosaed S, Smith AK, Liu JHK, Minckler DS, Fitzgerald RL, Grelotti D, Sones E, Weinreb RN, Marcotte TD. The Relationship Between Plasma Tetrahydrocannabinol Levels and Intraocular Pressure in Healthy Adult Subjects. Front Med 2022;8:736792. [DOI: 10.3389/fmed.2021.736792] [Reference Citation Analysis]
2 Jordan E, Nguyen GN, Piechot A, Kayser O. Cannabinoids as New Drug Candidates for the Treatment of Glaucoma. Planta Med 2022. [PMID: 35299275 DOI: 10.1055/a-1665-3100] [Reference Citation Analysis]
3 Miller S, Daily L, Leishman E, Bradshaw H, Straiker A. Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure. Invest Ophthalmol Vis Sci 2018;59:5904-11. [PMID: 30550613 DOI: 10.1167/iovs.18-24838] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]